A groundbreaking study reveals that Guardant Reveal's liquid biopsy detects immunotherapy responses earlier, enhancing ...

Liquid biopsy is a new technique that makes it easier to identify and monitor lung cancer without surgery. In India, this ...

Guardant Health raised its FY2025 sales guidance from $880.00 million-$890.00 million to $915.00 million-$925.00 million.

UChicago researchers have developed a new blood test that uses RNA modifications to detect early-stage colorectal cancer with ...

Q2 2025 Management View Helmy Eltoukhy, Co-CEO, stated that "Q2 marked another exceptional quarter for Guardant. We continue to build momentum across oncology, biopharma and screening business lines, ...

Fort Myers-based NeoGenomics reported mixed results for the second quarter. Revenue grew 10% over the year, but the net loss ...

Gnosis, a Southern California-based diagnostic lab advancing women's health through molecular innovation, today announced the national launch of EdenDx, which stands for Early Detection for ...

(NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the launch of NEO PanTracer™ LBx, a blood-based comprehensive genomic profiling (CGP) ...

A research team has developed a technology that distinguishes lung cancer gene mutations solely by measuring the "stiffness" ...

Urologic cancers, which include prostate, bladder, and kidney malignancies, pose significant global health challenges due to ...

Biopsy followed by gross excision was associated with significantly greater survival outcomes than wide local excision for acral lentiginous melanoma.

Using both liquid and tissue biopsies to guide targeted treatment may improve outcomes in patients with solid tumor malignancies.